Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer (European Urology)

Despite the development of novel androgen deprivation therapies (ADTs) such as enzalutamide and abiraterone, metastatic castration-resistant prostate cancer (mCRPC) remains incurable. Developments in massively parallel DNA sequencing and computational biology have allowed unprecedented insights into the molecular alterations underlying prostate tumorigenesis and progression [1-5]. Moreover, prognostic biomarkers of aggressive localized disease have been developed using whole-genome sequencing (WGS) and related technologies [1,6].